[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-339899-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-339899-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","insights-into-the-gene-expression-profile-of-classical-hodgkin-lymphoma-a-study-towards-discovery-of-novel-therapeutic-targets","Insights into the Gene Expression Proﬁle of Classical Hodgkin Lymphoma: A Study towards Discovery of Novel Therapeutic Targets","","Classical Hodgkin lymphoma (cHL) is a common B-cell cancer with major clinical burden, and relapse remains a persistent challenge despite chemotherapy. This study retrieved microarray gene expression data from cHL patients to identify differentially expressed genes and then performed functional and network annotation of upregulated genes. Matrix metallopeptidase 12 (MMP12) and C-C motif metallopeptidase ligand 22 (CCL22) emerged as key players in cHL progression and cancer-related pathways. MMP12 was prioritized for inhibition via docking and simulation, where known compounds showed strong binding and supportive MMGBSA/MMPBSA scores.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/insights-into-the-gene-expression-profile-of-classical-hodgkin-lymphoma-a-study-towards-discovery-of-novel-therapeutic-targets/339899/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/insights-into-the-gene-expression-profile-of-classical-hodgkin-lymphoma-a-study-towards-discovery-of-novel-therapeutic-targets/339899.png","ImageObject",300,407,{"name":42,"@type":43},"Asher","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-04","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What was the main goal of the study on classical Hodgkin lymphoma (cHL)?","Question",{"text":63,"@type":64},"To discover potential biomarkers from cHL-specific gene expression data and explore anticancer inhibitors that could target the identified biomarkers.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which genes were highlighted as actively involved in cHL progression?",{"text":68,"@type":64},"The study emphasized upregulated genes MMP12 and CCL22, linking them to cancer-related pathways and strong associations with other cancer-promoting genes.",{"name":70,"@type":61,"acceptedAnswer":71},"How was MMP12 evaluated as a therapeutic target?",{"text":72,"@type":64},"MMP12 was selected for inhibition and evaluated using docking and simulation strategies, followed by MMGBSA/MMPBSA scoring to support effective ligand binding.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},339899,1790197758,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},687197207639,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","molecules   \nArticle  \nInsights into the Gene Expression Proﬁle of Classical Hodgkin Lymphoma: A Study towards Discovery of Novel Therapeutic Targets  \nAbdulaziz A. Aloliqi   \nCitation: Aloliqi, A.A. Insights into the Gene Expression Proﬁle of Classical Hodgkin Lymphoma: A Study towards Discovery of Novel Therapeutic Targets. Molecules 2024, 29, 3476. [https://doi.org/10.3390/](https://doi.org/10.3390/)[ ](https://doi.org/10.3390/)molecules29153476  \nAcademic Editors: Carlotta Granchi and Giulia Bononi  \nReceived: 11 June 2024  \nRevised: 18 July 2024  \nAccepted: 22 July 2024  \nPublished: 25 July 2024  \nCopyright: © 2024 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \nDepartment of Basic Health Sciences, College of Applied Medical Sciences, Qassim University, Buraydah 52571, Saudi Arabia; [aaalieky@qu.edu.sa](aaalieky@qu.edu.sa)  \nAbstract: Classical Hodgkin lymphoma (cHL) is a common B-cell cancer and a signiﬁcant health concern, especially in Western and Asian countries. Despite the effectiveness of chemotherapy, many relapse cases are being reported, highlighting the need for improved treatments. This study aimed to address this issue by discovering biomarkers through the analysis of gene expression data speciﬁc to cHL. Additionally, potential anticancer inhibitors were explored to target the discovered biomarkers. This study proceeded by retrieving microarray gene expression data from cHL patients, which was then analyzed to identify signiﬁcant differentially expressed genes (DEGs) . Functional and network annotation of the upregulated genes revealed the active involvement of matrix metallopeptidase 12 (MMP12) and C-C motif metallopeptidase ligand 22 (CCL22) genes in the progression of cHL. Additionally, the mentioned genes were found to be actively involved in cancer-related pathways, i.e., oxidative phosphorylation, complement pathway, myc_targets_v1 pathway, TNFA signaling via NFKB, etc., and showed strong associations with other genes known to promote cancer progression. MMP12, topping the list with a logFC value of +6.6378, was selected for inhibition using docking and simulation strategies. The known anticancer compounds were docked into the active site of the MMP12 molecular structure, revealing signiﬁcant binding scores of 􀀀7.7 kcal/mol and 􀀀7.6 kcal/mol for BDC_ 24037121 and BDC_ 27854277, respectively. Simulation studies of the docked complexes further supported the effective binding of the ligands, yielding MMGBSA and MMPBSA scores of 􀀀78 .08 kcal/mol and 􀀀82 .05 kcal/mol for MMP12-BDC_ 24037121 and 􀀀48 .79 kcal/mol and 􀀀49.67 kcal/mol for MMP12-BDC_ 27854277, respectively. Our ﬁndings highlight the active role of MMP12 in the progression of cHL, with known compounds effectively inhibiting its function and potentially halting the advancement of cHL. Further exploration of downregulated genes is warranted, as associated genes may play a role in cHL. Additionally, CCL22 should be considered for further investigation due to its signiﬁcant role in the progression of cHL.  \nKeywords: classical Hodgkin lymphoma; microarray data analysis; docking; simulations; gene expression; drug target; cancer therapy  \n1. Introduction  \nIn 1832, Thomas Hodgkin identiﬁed classical Hodgkin lymphoma (cHL), a cancer of the lymphatic system that affects normal B-cells [1] . It occurs at a rate of 2–3 instances per 100,000 individuals annually in prosperous countries. Approximately 25–40% of cases of cHL may be causally linked to Epstein–Barr virus infections. These cases may also include individuals with a personal history of autoimmune diseases or immunological deﬁciencies, including HIV infection and cancers that develop from low-grade B-cell lymph","cbCaiebX4GWAAc2n","https://ap.wps.com/l/cbCaiebX4GWAAc2n","pdf",8270877,28,"English","# Abstract\n## Keywords\n## Introduction","[{\"question\":\"What was the main goal of the study on classical Hodgkin lymphoma (cHL)?\",\"answer\":\"To discover potential biomarkers from cHL-specific gene expression data and explore anticancer inhibitors that could target the identified biomarkers.\"},{\"question\":\"Which genes were highlighted as actively involved in cHL progression?\",\"answer\":\"The study emphasized upregulated genes MMP12 and CCL22, linking them to cancer-related pathways and strong associations with other cancer-promoting genes.\"},{\"question\":\"How was MMP12 evaluated as a therapeutic target?\",\"answer\":\"MMP12 was selected for inhibition and evaluated using docking and simulation strategies, followed by MMGBSA/MMPBSA scoring to support effective ligand binding.\"}]","Insights into the Gene Expression Proﬁle of Classical Hodgkin Lymphoma: A Study towards Discovery of Novel Therapeutic Targets | PDF",1790033013,71,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/46065c2aaeee12d6458d93395b129fbb.webp",983,1390,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/31f784ed383e5531a6ba699c67a1a745.webp",982,1388,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c82174c2d83e71612bac24efe9e7ec0f.webp",981,1387,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e88883b13d83a3d5a78b66c8a1a14eb4.webp",980,1385]